Grant v. Csl Behring LLC

CourtDistrict Court, District of Columbia
DecidedMarch 31, 2023
DocketCivil Action No. 2021-2044
StatusPublished

This text of Grant v. Csl Behring LLC (Grant v. Csl Behring LLC) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Grant v. Csl Behring LLC, (D.D.C. 2023).

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

JULIA GRANT,

Plaintiff,

v. Civil Action No. 1:21-cv-02044 (CJN)

CSL BEHRING, LLC,

Defendant.

MEMORANDUM OPINION

In March 2021, biopharmaceutical company CSL Behring, LLC terminated the

employment of Julia Grant, who then initiated this lawsuit for discrimination and retaliation under

the D.C. Human Rights Act. CSL has moved for summary judgment on all claims, arguing that

Grant’s termination was not motivated by unlawful discrimination or retaliation, but by a company

reorganization. Grant maintains that this stated reason is pretextual. For the reasons explained

below, the Court grants summary judgment to CSL on Grant’s retaliation claim, but denies

summary judgment on her age and sex discrimination claims.

I. Background

CSL is a biopharmaceutical company that “researches, develops, manufactures, and

markets plasma protein biotherapies . . . used to treat serious and rare medical conditions.”1 Def.’s

Statement of Facts (“Def.’s SOMF”) ¶ 1, ECF No. 24. On May 1, 2017, CSL hired Grant as

Director of U.S. Healthcare Policy and Federal Affairs (or more simply, “Director of Federal

1 Unless otherwise noted, these facts are undisputed or established by uncontroverted evidence, at least at the summary judgment stage.

1 Government Affairs”). Id. ¶ 2. Grant remained in that position throughout the entirety of her

employment with the company. Id. ¶ 3. Her job duties included “forging relationships” in

Washington, D.C., “to help advance CSL’s position in policy” on matters that concerned the

company, like patient access or new biopharmaceutical products. Def.’s Ex. C (Wixted Corp. Tr.)

at 28; see Def.’s SOMF ¶ 18 (describing Grant’s role as “focusing on the legislative process and

driving advocacy initiatives within Congress”).

Grant’s direct supervisor during the entirety of her employment at CSL was Patrick Collins,

whose title was Senior Director of Global Healthcare Policy and External Affairs. Def.’s SOMF

¶ 6. Michael Ruggiero joined the company in June 2019 as the Senior Vice President of Global

Healthcare Policy and External Affairs; among other things, Ruggiero was Collins’s superior. Id.

¶ 7; Def.’s Ex. C (Wixted Corp. Tr.) at 23. Ruggiero was tasked with “review[ing] the organization

and prepar[ing] it for the future.” Def.’s Ex. F (Ruggiero Tr.) at 46–47. In other words, he assessed

the structure of the organization and considered how to improve it. See id. at 45. Although the

global government affairs function of CSL also had teams covering policy matters in other parts

of the world, the reorganization as relevant here concerned only the group focused on North

American affairs.

As it stood when Ruggiero joined, the North America government affairs group consisted

of six employees subordinate to him. Collins (again, Senior Director of Global Healthcare Policy

and External Affairs) reported to Ruggiero and supervised both Grant (again, Director of Federal

Government Affairs) and Karla White (Director of State Government Affairs). See Def.’s Ex. G

(Org. Charts) at 3361. White had three direct reports, and Grant had none. Pl.’s Statement of

Facts (“Pl.’s SOMF”) ¶¶ 59–60, ECF No. 25; Def.’s Resp. to Pl.’s SOMF (“Def.’s Resp.”)

2 ¶¶ 59–60, ECF No. 26-2. Grant’s office was located in Washington, D.C., while Collins was based

in Pennsylvania. Pl.’s SOMF ¶ 4.

A. Restructuring of the North America Government Affairs Group

The Parties dispute how best to characterize the effect of Ruggiero’s reorganization. What

is clear is that Ruggiero added an Executive Director-level position to lead the North America

group (called the “Head of North America Healthcare Policy & External Affairs”), who would

supervise a Senior Director of Federal Affairs and the existing Director of State Government

Affairs. Def.’s SOMF ¶ 13; see Def.’s Ex. G (Org. Charts) at 3366. The Senior Director of Federal

Affairs would have no direct reports, and the Director of State Government Affairs would have

three. See Def.’s Ex. G (Org. Charts) at 3366. And key to this lawsuit, there would no longer be

a Director of Federal Affairs—the position held by Grant. See id.; Def.’s SOMF ¶ 16.

According to CSL, pairing the new Executive Director with a Senior Director instead of a

Director focused on federal affairs within the North America group would involve “sacrific[ing]

the tactical execution of congressional strategy performed by a Director level role,” but the Senior

Director would have the benefit of “a deep understanding of CSL’s business” when developing

policy strategy. Def.’s SOMF ¶¶ 15–18. Outside consultants could fill the gap left by the loss of

a Director-level role by executing the more “tactical elements” of advocacy work. Id. ¶¶ 16–17.

After Ruggiero first proposed a restructuring in approximately April 2020, he went on to

produce multiple iterations of the reorganization plan over the course of the next several months.

Id. ¶ 22; Def.’s Ex. E (CSL Interrog. Resps.) ¶ 8; see Pl.’s Ex. 1 (Wixted Corp. Tr.) at 225–28.

One aspect of the initial plan, which lasted through many iterations, was to eliminate both Grant’s

Director role and Collins’s Senior Director role, but then fill the position of Senior Director of

Federal Affairs with a new hire. See Def.’s Ex. G (Org. Charts) at 3362, 3364; Pl.’s Ex. 1 (Wixted

3 Corp. Tr.) at 148–49. Having experienced a successful virtual working environment during the

COVID-19 pandemic, however, CSL later decided that Collins could fill the Senior Director

position—which was supposed to be based in Washington, D.C.—from his location in

Pennsylvania. Def.’s SOMF ¶ 29. Ruggiero revised the plan to retain Collins in the Senior

Director role, but the plan still involved terminating Grant. Id. ¶¶ 33–34. Ruggiero selected

Mary-Lacey Reuther to fill the Executive Director role. Id. ¶¶ 35–36.

The way Grant sees it, the reorganization did not involve the creation of any new roles, but

merely their renaming, as duties were shifted among members of the team. In Grant’s view,

Reuther was placed in Collins’s position; Collins was placed in Grant’s position; and Grant was

terminated. See Pl.’s Resp. to Def.’s SOMF (“Pl.’s Resp.”) ¶¶ 13, 33–35, ECF No. 25.

B. CSL Investigation

In early October 2020, Collins forwarded an email exchange to Grant and the Nickles

Group, a political consulting firm, regarding the possibility of having then-First Lady Melania

Trump donate convalescent plasma following her recovery from COVID-19 to publicly promote

plasma donation. Def.’s SOMF ¶¶ 38–39; Def.’s Ex. B (Grant Tr.) at 69, 106; see Pl.’s SOMF

¶ 18. Grant replied to Collins and Ruggiero asking why she was not included in the original

discussion about the idea. Def.’s SOMF ¶ 40. After receiving Grant’s reply, Collins called her

and advised her to recall the email, but Grant informed Collins that she did not know how to recall

emails and that she was “tired” of “being marginalized, cut out, [and] not included” by Collins and

Ruggiero. Def.’s Ex. B (Grant Tr.) at 110; Pl.’s Ex. 4 (Collins Tr.) at 93–97. Grant also told

Collins that she was “not afraid” of him and Ruggiero. Def.’s SOMF ¶ 41; Def.’s Ex. B (Grant

Tr.) at 110–11. Collins understood from the exchange that Grant was raising a concern about

CSL’s treatment of women. Def.’s SOMF ¶ 42.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gaujacq v. EDF, Inc.
601 F.3d 565 (D.C. Circuit, 2010)
McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Stella, Marie v. v. Mineta, Norman Y.
284 F.3d 135 (D.C. Circuit, 2002)
Murray, Lucy v. Gilmore, David
406 F.3d 708 (D.C. Circuit, 2005)
Woodruff, Phillip v. Peters, Mary
482 F.3d 521 (D.C. Circuit, 2007)
Brady v. Office of the Sergeant at Arms
520 F.3d 490 (D.C. Circuit, 2008)
Taylor v. Solis
571 F.3d 1313 (D.C. Circuit, 2009)
Etim U. Aka v. Washington Hospital Center
156 F.3d 1284 (D.C. Circuit, 1998)
Reeves v. Sanderson Plumbing Products, Inc.
530 U.S. 133 (Supreme Court, 2000)
McFarland v. George Washington University
935 A.2d 337 (District of Columbia Court of Appeals, 2007)
Hollins v. Federal National Mortgage Ass'n
760 A.2d 563 (District of Columbia Court of Appeals, 2000)
Estenos v. PAHO/WHO Federal Credit Union
952 A.2d 878 (District of Columbia Court of Appeals, 2008)
Daka, Inc. v. Breiner
711 A.2d 86 (District of Columbia Court of Appeals, 1998)
Furline v. Morrison
953 A.2d 344 (District of Columbia Court of Appeals, 2008)
Cain v. REINOSO
43 A.3d 302 (District of Columbia Court of Appeals, 2012)
Brandli v. Micrus Endovascular Corporation
209 F. Supp. 3d 356 (District of Columbia, 2016)
Carpenter v. Federal National Mortgage Ass'n
174 F.3d 231 (D.C. Circuit, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
Grant v. Csl Behring LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/grant-v-csl-behring-llc-dcd-2023.